![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Tanner to distribute Versacloz in areas outside of the U.S where the product is not yet registered. Versacloz is indicated for the treatment of severely ill patients with schizophrenia who fail to respond to standard antipsychotic treatment.
Lead Product(s): Clozapine
Therapeutic Area: Psychiatry/Psychology Product Name: Versacloz
Highest Development Status: Approved Product Type: Small molecule
Recipient: Tanner Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2020